NasdaqGS - Nasdaq Real Time Price USD

AlloVir, Inc. (ALVR)

0.8000

+0.0200

(+2.56%)

At close: April 25 at 4:00 PM EDT

0.7760

-0.02

(-3.00%)

After hours: April 25 at 4:21 PM EDT

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Simply Wall St. 2 months ago

ALVR
+2.56%
Are Medical Stocks Lagging AlloVir (ALVR) This Year?

Here is how AlloVir, Inc. (ALVR) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.

Zacks 2 months ago

ALVR
+2.56%
ARQT
Down -72.39% in 4 Weeks, Here's Why You Should You Buy the Dip in AlloVir, Inc. (ALVR)

AlloVir, Inc. (ALVR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks 3 months ago

ALVR
+2.56%
Karuna downgraded, Arm target raised: Wall Street's top analyst calls

Karuna downgraded, Arm target raised: Wall Street's top analyst calls

The Fly 3 months ago

KRTX

ALVR
+2.56%
RVPHW
Nike downgraded, Waste Management upgraded: Wall Street's top analyst calls

Nike downgraded, Waste Management upgraded: Wall Street's top analyst calls

The Fly 4 months ago

ORCL

NKE

AMP
AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy

Company to discontinue its three Phase 3 posoleucel studies following separate, pre-planned DSMB futility analyses concluding the studies were unlikely to meet their primary endpoints; no safety concerns identified Company to prioritize capital preservation and review strategic options AlloVir reported $213.3 million in cash, cash equivalents, and short-term investments as of September 30, 2023 WALTHAM, Mass., Dec. 22, 2023 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), an allogeneic T cell i

GlobeNewswire 4 months ago

ALVR
+2.56%
Penny Stock Jackpots: 3 High-Stakes Picks With 10-Bagger Potential

There are penny stocks and then are penny stock picks that are so outrageously wild that they should never be considered unless one is gambling with pocket change. And by pocket change, I’m talking almost literally. You’ve heard the expression about investing no more than you can afford to lose? Here, you don’t even want to get anywhere near that point. Let’s consider a standard sports car. Generally, the rev limiter will kick in at around 6,800 revolutions per minute (RPM). Basically, the purpo

InvestorPlace 4 months ago

PAVM

ALVR
+2.56%
IPSC
AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference

WALTHAM, Mass., November 16, 2023--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York City, NY on Tuesday, November 28, 2023 at 10:00 a.m. ET.

Business Wire 5 months ago

ALVR
+2.56%
AlloVir Inc (ALVR) Reports Q3 2023 Financial Results

Company's Cash Position Strengthens, Paving the Way for Pivotal Trial Data Readouts

GuruFocus.com 5 months ago

ALVR
+2.56%
AlloVir Reports Third Quarter 2023 Financial Results

WALTHAM, Mass., November 02, 2023--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today reported financial results from the third quarter ended September 30, 2023. AlloVir continues to progress its highly innovative lead therapeutic candidate, posoleucel, by enrolling globally in three Phase 3 trials for first-to-market indications. AlloVir is in a position of strength with significant financial resources to support operations through topline data re

Business Wire 5 months ago

ALVR
+2.56%
Why AlloVir Stock Dropped Today

AlloVir briefly plunged amid concerns over selling pressure related to a recent lock-up agreement expiration.

Motley Fool 7 months ago

ALVR
+2.56%
We're Keeping An Eye On AlloVir's (NASDAQ:ALVR) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Simply Wall St. 7 months ago

ALVR
+2.56%
These 2 “Strong Buy” Penny Stocks Could Soar to $17 (Or Higher), Say Analysts

Let’s take a moment to talk about opportunity, share price, and risk/reward considerations. These are some of the factors investors must consider when moving into penny stocks – and we haven’t even touched on the fundamental soundness of the company or its business model. Penny stocks – as their name suggests, they once traded for just a pennies per share, but these days are considered those equities trading at less than $5 – are a challenging market niche. The penny stock critics make valid poi

TipRanks 7 months ago

DCTH

ALVR
+2.56%
AlloVir to Present at Upcoming Investor Conferences

WALTHAM, Mass., August 28, 2023--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in the following upcoming investor conferences:

Business Wire 7 months ago

ALVR
+2.56%
AlloVir Reports Second Quarter 2023 Financial Results

WALTHAM, Mass., August 03, 2023--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today reported financial results from the second quarter ended June 30, 2023. The company shared progress across its allogeneic, off-the-shelf virus-specific T cell (VST) programs, including its lead investigational therapy, posoleucel, for prevention and treatment of life-threatening infections and diseases from up to six viruses that commonly impact patients following a

Business Wire 8 months ago

ALVR
+2.56%
Eliem (ELYM) to Explore Strategic Options, Stock Rises 6%

Eliem (ELYM) announces its decision to halt its Kv7 development program in its quest to explore strategic alternatives. The stock of the company rises 6% in response on Thursday.

Zacks 9 months ago

ELYM

FGEN

ALVR
+2.56%
Journey Medical (DERM) to Post Skin Disease Data, Stock Rises 26%

Journey Medical (DERM) rises 26% on Monday after announcing the tentative date for reporting top-line results from its late-stage studies evaluating DFD-29 in treating papulopustular rosacea.

Zacks 9 months ago

DERM

ALVR
+2.56%
AKBA
AlloVir, Inc. (ALVR) Upgraded to Buy: Here's Why

AlloVir, Inc. (ALVR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 9 months ago

ALVR
+2.56%
Why Shares of AlloVir Plummeted This Week

Shares of AlloVir (NASDAQ: ALVR) were down 39.8% for the week as of early Friday afternoon, after being down as much as 42.8%, according to data provided by S&P Global Market Intelligence. On Wednesday, the company said it was undertaking a public offering of shares worth $75 million to raise money. AlloVir is selling 20 million shares at $3.75 a share.

Motley Fool 9 months ago

ALVR
+2.56%
AlloVir Announces Pricing of Public Offering of Common Stock

WALTHAM, Mass., June 22, 2023--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $3.75 per share. The gross proceeds to AlloVir from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be $75.0 million. All shares in the offering are to be sold by AlloVir. In addition,

Business Wire 9 months ago

ALVR
+2.56%

Performance Overview

Return	ALVR	S&P 500
YTD	+17.65%	+5.84%
1-Year	-78.20%	+22.03%
3-Year	-96.42%	+20.77%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AlloVir, Inc. (ALVR)

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

Are Medical Stocks Lagging AlloVir (ALVR) This Year?

Down -72.39% in 4 Weeks, Here's Why You Should You Buy the Dip in AlloVir, Inc. (ALVR)

Karuna downgraded, Arm target raised: Wall Street's top analyst calls

Nike downgraded, Waste Management upgraded: Wall Street's top analyst calls

AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy

Penny Stock Jackpots: 3 High-Stakes Picks With 10-Bagger Potential

AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference

AlloVir Inc (ALVR) Reports Q3 2023 Financial Results

AlloVir Reports Third Quarter 2023 Financial Results

Why AlloVir Stock Dropped Today

We're Keeping An Eye On AlloVir's (NASDAQ:ALVR) Cash Burn Rate

These 2 “Strong Buy” Penny Stocks Could Soar to $17 (Or Higher), Say Analysts

AlloVir to Present at Upcoming Investor Conferences

AlloVir Reports Second Quarter 2023 Financial Results

Eliem (ELYM) to Explore Strategic Options, Stock Rises 6%

Journey Medical (DERM) to Post Skin Disease Data, Stock Rises 26%

AlloVir, Inc. (ALVR) Upgraded to Buy: Here's Why

Why Shares of AlloVir Plummeted This Week

AlloVir Announces Pricing of Public Offering of Common Stock

Performance Overview